Убиквитин-независимый протеолиз основного белка миелина и его роль в развитии экспериментального аутоиммунного энцефаломиелита (1105762), страница 20
Текст из файла (страница 20)
Oksenberg, M. A.Panzara, A. B. Begovich, et al. // Nature. – 1993. – Vol. 362, no. 6415. – P. 68-70.84.High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosisrevealed by novel flow cytometric assay / M. P. Crawford, S. X. Yan, S. B. Ortega, et al. //Blood. – 2004. – Vol. 103, no. 11. – P. 4222-4231.85.Immunohistological analysis of T lymphocyte subsets in the central nervous system inchronic progressive multiple sclerosis / J. Booss, M. M. Esiri, W.
W. Tourtellotte, et al. // JNeurol Sci. – 1983. – Vol. 62, no. 1-3. – P. 219-232.86.Expression of major histocompatibility complex class I molecules on the different celltypes in multiple sclerosis lesions / R. Hoftberger, F. Aboul-Enein, W. Brueck, et al. // BrainPathol. – 2004. – Vol. 14, no. 1. – P. 43-50.10487.Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss / B.Sobottka, M. D. Harrer, U. Ziegler, et al. // Am J Pathol. – 2009. – Vol.
175, no. 3. – P. 11601166.88.MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptidespecific CD8 T lymphocytes / A. Jurewicz, W. E. Biddison and J. P. Antel // J Immunol. – 1998.– Vol. 160, no. 6. – P. 3056-3059.89.Experimental autoimmune encephalomyelitis mediated by CD8+ T cells / Q. Ji and J.Goverman // Ann N Y Acad Sci. – 2007. – Vol. 1103, no. – P. 157-166.90.The role of regulatory T cells in multiple sclerosis / A.
L. Zozulya and H. Wiendl // NatClin Pract Neurol. – 2008. – Vol. 4, no. 7. – P. 384-398.91.Specificity requirements for selection and effector functions of CD25+4+ regulatory Tcells in anti-myelin basic protein T cell receptor transgenic mice / S. Hori, M. Haury, A.Coutinho, et al. // Proc Natl Acad Sci U S A. – 2002. – Vol. 99, no.
12. – P. 8213-8218.92.Multiple sclerosis / J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, et al. // N Engl JMed. – 2000. – Vol. 343, no. 13. – P. 938-952.93.Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic proteinin multiple sclerosis and other neurological diseases: a comparative study / M.
Reindl, C.Linington, U. Brehm, et al. // Brain. – 1999. – Vol. 122 ( Pt 11), no. – P. 2047-2056.94.Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen /N. A. Ponomarenko, O. M. Durova, Vorobiev, II, et al. // Proc Natl Acad Sci U S A. – 2006. –Vol. 103, no. 2. – P. 281-286.95.Interaction forces and adhesion of supported myelin lipid bilayers modulated by myelinbasic protein / Y. Min, K. Kristiansen, J. M. Boggs, et al. // Proc Natl Acad Sci U S A. – 2009. –Vol.
106, no. 9. – P. 3154-3159.96.Основной белок миелина. Строение, свойства, функции, роль в диагностикедимиелинизирующих заболеваний. / В. П. Чехонин, О. И. Гурина, Т. Б. Дмитриева, et al. //Вопросы медецинской химии. – 2000. – Vol. 6, no. – P. 10-27.97.Основной белок миелина. Строение, свойства, функции, роль в диагностикедемиелинизирующих заболеваний. / В. П. Чехонин, О. И. Гурина, Т.
Б. Дмитриева, et al. //Вопросы медицинской химии. – 2000. – Vol. 6, no. – P. 10-27.98.Myelin in multiple sclerosis is developmentally immature / M. A. Moscarello, D. D.Wood, C. Ackerley, et al. // J Clin Invest. – 1994. – Vol. 94, no. 1. – P. 146-154.10599.Acute multiple sclerosis (Marburg type) is associated with developmentally immaturemyelin basic protein / D. D. Wood, J. M. Bilbao, P. O'Connors, et al. // Ann Neurol.
– 1996. –Vol. 40, no. 1. – P. 18-24.100. Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes animmunodominant epitope / A. A. Musse, J. M. Boggs and G. Harauz // Proc Natl Acad Sci U SA. – 2006. – Vol. 103, no. 12. – P. 4422-4427.101. Structural insight into the role of myelin basic protein in multiple sclerosis / C.
Husted //Proc Natl Acad Sci U S A. – 2006. – Vol. 103, no. 12. – P. 4339-4340.102. Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues ofmyelin basic protein on its structure and susceptibility to digestion by cathepsin D / L. B.Pritzker, S. Joshi, J.
J. Gowan, et al. // Biochemistry. – 2000. – Vol. 39, no. 18. – P. 5374-5381.103. Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1(MMP-3) and release of an immunodominant epitope / C. A. D'Souza and M. A. Moscarello //Neurochem Res. – 2006. – Vol. 31, no.
8. – P. 1045-1054.104. Myelin basic protein, an autoantigen in multiple sclerosis, is selectively processed byhuman trypsin 4 / P. Medveczky, J. Antal, A. Patthy, et al. // FEBS Lett. – 2006. – Vol. 580, no.2. – P. 545-552.105. Increased calpain expression in activated glial and inflammatory cells in experimentalallergic encephalomyelitis / D. C. Shields, W. R. Tyor, G. E. Deibler, et al.
// Proc Natl Acad SciU S A. – 1998. – Vol. 95, no. 10. – P. 5768-5772.106. Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source ofimmunogenic peptides in autoimmune multiple sclerosis / S. A. Shiryaev, A. Y. Savinov, P.Cieplak, et al. // PLoS One. – 2009. – Vol. 4, no. 3. – P. e4952.107.
Autocatalytic cleavage of myelin basic protein: an alternative to molecular mimicry / C.A. D'Souza, D. D. Wood, Y. M. She, et al. // Biochemistry. – 2005. – Vol. 44, no. 38. – P.12905-12913.108. Site-specific degradation of myelin basic protein by the proteasome / A. A. Belogurov,Jr., N. A. Ponomarenko, V. M. Govorun, et al. // Dokl Biochem Biophys. – 2009. – Vol. 425, no.– P. 68-72.109. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidativestress / U. Seifert, L.
P. Bialy, F. Ebstein, et al. // Cell. – 2010. – Vol. 142, no. 4. – P. 613-624.110. Proteasomes in immune cells: more than peptide producers? / M. Groettrup, C. J. Kirkand M. Basler // Nat Rev Immunol. – 2010. – Vol. 10, no. 1. – P. 73-78.106111. Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral andinnate immune responses / S.
E. Hensley, D. Zanker, B. P. Dolan, et al. // J Immunol. – 2010. –Vol. 184, no. 8. – P. 4115-4122.112. Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces therisk to develop multiple sclerosis in Italian female population / M. Mishto, E. Bellavista, C.Ligorio, et al. // PLoS One. – 2010. – Vol.
5, no. 2. – P. e9287.113. Changes in 20S subunit composition are largely responsible for altered proteasomalactivities in experimental autoimmune encephalomyelitis / J. Zheng, A. Dasgupta and O. A.Bizzozero // J Neurochem. – 2012. – Vol. 121, no. 3. – P. 486-494.114. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune centralnervous system inflammation / N.
Fissolo, M. Kraus, M. Reich, et al. // Eur J Immunol. – 2008. –Vol. 38, no. 9. – P. 2401-2411.115. Cross-reactions and specificities of monoclonal antibodies against myelin basic proteinand against the synthetic copolymer 1 / D. Teitelbaum, R. Aharoni, M. Sela, et al. // Proc NatlAcad Sci U S A. – 1991.
– Vol. 88, no. 21. – P. 9528-9532.116. Molecular mechanisms of the anti-inflammatory functions of interferons / P. Kovarik, I.Sauer and B. Schaljo // Immunobiology. – 2007. – Vol. 212, no. 9-10. – P. 895-901.117. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind,randomised, multicentre trial / H.
P. Hartung, R. Gonsette, N. Konig, et al. // Lancet. – 2002. –Vol. 360, no. 9350. – P. 2018-2025.118. Natalizumab for multiple sclerosis / R. M. Ransohoff // N Engl J Med. – 2007. – Vol.356, no. 25. – P. 2622-2629.119. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients/ A. H. Cross, J. L. Stark, J.
Lauber, et al. // J Neuroimmunol. – 2006. – Vol. 180, no. 1-2. – P.63-70.120. B-cells in multiple sclerosis / M. Duddy and A. Bar-Or // Int MS J. – 2006. – Vol. 13, no.3. – P. 84-90.121. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis / S. L. Hauser, E.Waubant, D. L. Arnold, et al. // N Engl J Med. – 2008.
– Vol. 358, no. 7. – P. 676-688.122. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptordependent mechanisms during anti-CD20 antibody immunotherapy / J. Uchida, Y. Hamaguchi,J. A. Oliver, et al. // J Exp Med. – 2004. – Vol. 199, no.
12. – P. 1659-1669.107123. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial /A. Bar-Or, P. A. Calabresi, D. Arnold, et al. // Ann Neurol. – 2008. – Vol. 63, no. 3. – P. 395400.124. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells /S.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
